Vickie E Baracos

List of Publications by Year
in descending order

267 papers	36,914 citations	10070 75 h-index	3688 186 g-index
270 all docs	270 docs citations	270 times ranked	28569 citing authors

#	Article	IF	Citations
1	Comparison of body composition techniques in Portuguese patients with gastrointestinal cancer. Annals of Medicine, 2024, 51, 158-158.	1.5	1
2	Factors Associated with Oral Cancerous and Precancerous Lesions in an Underserved Community: A Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2022, 19, 1297.	1.2	3
3	Piloting a training program in computed tomography skeletal muscle assessment for registered dietitians. Journal of Parenteral and Enteral Nutrition, 2022, 46, 1317-1325.	1.3	7
4	Myosteatosis in Cirrhosis: A Review of Diagnosis, Pathophysiological Mechanisms and Potential Interventions. Cells, 2022, 11, 1216.	1.8	24
5	Assessing dynamic change in muscle during treatment of patients with cancer: Precision testing standards. Clinical Nutrition, 2022, 41, 1059-1065.	2.3	9
6	Psychological symptoms of illness and emotional distress in advanced cancer cachexia. Current Opinion in Clinical Nutrition and Metabolic Care, 2022, 25, 167-172.	1.3	20
7	Skeletal Muscle Pathological Fat Infiltration (Myosteatosis) Is Associated with Higher Mortality in Patients with Cirrhosis. Cells, 2022, 11, 1345.	1.8	20
8	Retrospective study of factors associated with late detection of oral cancer in alberta: A qualitative study. PLoS ONE, 2022, 17, e0266558.	1.1	1
9	The impact of cachexia on dietary intakes, symptoms, and quality of life in advanced cancer. JCSM Rapid Communications, 2022, 5, 162-170.	0.6	7
10	Adiposity in resectable colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 3614-3614.	0.8	0
11	Body Composition Influences Post-Operative Complications and 90-Day and Overall Survival in Pancreatic Surgery Patients. GE Portuguese Journal of Gastroenterology, 2021, 28, 13-25.	0.3	9
12	Response Regarding: Thigh Ultrasound Used to Identify Frail Elderly Patients With Sarcopenia Undergoing Surgery: A Pilot Study. Journal of Surgical Research, 2021, 260, 522-523.	0.8	0
13	Adequacy of nutritional support using computed tomography (CT) in patients with head and neck cancer (HNC) during chemo-radiotherapy (CRT). European Journal of Clinical Nutrition, 2021, 75, 1515-1519.	1.3	4
14	Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer. European Radiology, 2021, 31, 8662-8670.	2.3	24
15	ESPEN practical guideline: Clinical Nutrition in cancer. Clinical Nutrition, 2021, 40, 2898-2913.	2.3	472
16	Ectopic fat in liver and skeletal muscle is associated with shorter overall survival in patients with colorectal liver metastases. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 983-992.	2.9	9
17	Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors. Frontiers in Oncology, 2021, 11, 699668.	1.3	10
18	CT-based assessment of body composition and skeletal muscle in melanoma: A systematic review. Clinical Nutrition ESPEN, 2021, 45, 127-133.	0.5	3

#	Article	IF	Citations
19	Diagnostic criteria for cancer cachexia: reduced food intake and inflammation predict weight loss and survival in an international, multiâ€cohort analysis. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 1189-1202.	2.9	41
20	Depletion of essential fatty acids in muscle is associated with shorter survival of cancer patients undergoing surgery-preliminary report. Scientific Reports, 2021, 11, 23006.	1.6	1
21	Low muscle mass is associated with early termination of chemotherapy related to toxicity in patients with head and neck cancer. Clinical Nutrition, 2020, 39, 501-509.	2.3	48
22	Determinants of change in resting energy expenditure in patients with stage III/IV colorectal cancer. Clinical Nutrition, 2020, 39, 134-140.	2.3	21
23	Prevalence and prognostic significance of malnutrition in patients with cancers of the head and neck. Clinical Nutrition, 2020, 39, 901-909.	2.3	47
24	Cancerâ€Associated Malnutrition and CTâ€Ðefined Sarcopenia and Myosteatosis Are Endemic in Overweight and Obese Patients. Journal of Parenteral and Enteral Nutrition, 2020, 44, 227-238.	1.3	85
25	Profiling Determinants of Resting Energy Expenditure in Colorectal Cancer. Nutrition and Cancer, 2020, 72, 431-438.	0.9	5
26	Deep learning method for localization and segmentation of abdominal CT. Computerized Medical Imaging and Graphics, 2020, 85, 101776.	3.5	36
27	Sarcopenia Severity Based on Computed Tomography Image Analysis in Patients with Cirrhosis. Nutrients, 2020, 12, 3463.	1.7	23
28	Sarcopenia and low muscle radiodensity associate with impaired FEV₁ in allogeneic haematopoietic stem cell transplant recipients. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1570-1579.	2.9	19
29	Association of Low Muscle Mass and Low Muscle Radiodensity With Morbidity and Mortality for Colon Cancer Surgery. JAMA Surgery, 2020, 155, 942.	2.2	91
30	Thigh Ultrasound Used to Identify Frail Elderly Patients with Sarcopenia Undergoing Surgery: AÂPilot Study. Journal of Surgical Research, 2020, 256, 422-432.	0.8	14
31	Computed-Tomography Body Composition Analysis Complements Pre-Operative Nutrition Screening in Colorectal Cancer Patients on an Enhanced Recovery after Surgery Pathway. Nutrients, 2020, 12, 3745.	1.7	16
32	Management of Cancer Cachexia: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 2438-2453.	0.8	292
33	Dentition, nutritional status and adequacy of dietary intake in treatment naÃ¯ve head and neck cancer patients. Heliyon, 2020, 6, e03617.	1.4	5
34	Review article: prognostic significance of body composition abnormalities in patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2020, 52, 600-618.	1.9	45
35	Visceral Adipose Tissue Radiodensity Is Linked to Prognosis in Hepatocellular Carcinoma Patients Treated with Selective Internal Radiation Therapy. Cancers, 2020, 12, 356.	1.7	25
36	Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab / cytotoxic chemotherapy treatment for metastatic colorectal cancer. Clinical Nutrition, 2020, 39, 3319-3330.	2.3	5

#	Article	IF	Citations
37	Lipid is heterogeneously distributed in muscle and associates with low radiodensity in cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 735-747.	2.9	32
38	Evaluation of automated computed tomography segmentation to assess body composition and mortality associations in cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1258-1269.	2.9	79
39	Assessing dietary intake in accordance with guidelines: Useful correlations with an ingesta-Verbal/Visual Analogue Scale in medical oncology patients. Clinical Nutrition, 2019, 38, 1927-1935.	2.3	19
40	Rapid atrophy of cardiac left ventricular mass in patients with nonâ€small cell carcinoma of the lung. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 1070-1082.	2.9	21
41	Clinical and biological characterization of skeletal muscle tissue biopsies of surgical cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 1356-1377.	2.9	26
42	Accuracy of Resting Energy Expenditure Predictive Equations in Patients With Cancer. Nutrition in Clinical Practice, 2019, 34, 922-934.	1.1	19
43	Sarcopenia: A Time for Action. An SCWD Position Paper. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 956-961.	2.9	410
44	Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy. Radiation Oncology, 2019, 14, 166.	1.2	28
45	Immunohistochemical phenotyping of T cells, granulocytes, and phagocytes in the muscle of cancer patients: association with radiologically defined muscle mass and gene expression. Skeletal Muscle, 2019, 9, 24.	1.9	15
46	Integration of palliative, supportive, and nutritional care to alleviate eating-related distress among advanced cancer patients with cachexia and their family members. Critical Reviews in Oncology/Hematology, 2019, 143, 117-123.	2.0	58
47	Dietary patterns and their relationships to sarcopenia in Portuguese patients with gastrointestinal cancer: An exploratory study. Nutrition, 2019, 63-64, 193-199.	1.1	4
48	Change in Skeletal Muscle Following Resection of Stage Iâ€“III Colorectal Cancer is Predictive of Poor Survival: A Cohort Study. World Journal of Surgery, 2019, 43, 2518-2526.	0.8	20
49	A prospective study examining cachexia predictors in patients with incurable cancer. BMC Palliative Care, 2019, 18, 46.	0.8	21
50	Muscle segmentation in axial computed tomography (CT) images at the lumbar (L3) and thoracic (T4) levels for body composition analysis. Computerized Medical Imaging and Graphics, 2019, 75, 47-55.	3.5	61
51	Convergent neuronal projections from paraventricular nucleus, parabrachial nucleus, and brainstem onto gastrocnemius muscle, white and brown adipose tissue in male rats. Journal of Comparative Neurology, 2019, 527, 2826-2842.	0.9	14
52	The association of medical and demographic characteristics with sarcopenia and low muscle radiodensity in patients with nonmetastatic colorectal cancer. American Journal of Clinical Nutrition, 2019, 109, 615-625.	2.2	45
53	Cancer cachexia is defined by an ongoing loss of skeletal muscle mass. Annals of Palliative Medicine, 2019, 8, 3-12.	0.5	88
54	The Impact of Muscle and Adipose Tissue on Long-term Survival in Patients With Stage I to III Colorectal Cancer. Diseases of the Colon and Rectum, 2019, 62, 549-560.	0.7	98

#	Article	IF	Citations
55	A comparison of CT based measures of skeletal muscle mass and density from the Th4 and L3 levels in patients with advanced non-small-cell lung cancer. European Journal of Clinical Nutrition, 2019, 73, 1069-1076.	1.3	19
56	Host phenotype is associated with reduced survival independent of tumour biology in patients with colorectal liver metastases. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 123-130.	2.9	19
57	Undiagnosed cardiac deficits in non-small cell carcinoma patients in the candidate population for anti-cachexia clinical trials. Supportive Care in Cancer, 2019, 27, 1551-1561.	1.0	9
58	Poor Physical Function as a Marker of Sarcopenia in Adults with Class II/III Obesity. Current Developments in Nutrition, 2018, 2, nzx008.	0.1	6
59	Cancer cachexia: rationale for the MENAC (Multimodalâ€"Exercise, Nutrition and Anti-inflammatory) Tj ETQq1 1 0.784314 rgBT /Over	0.8	134
60	Barriers to the Interpretation of Body Composition in Colorectal Cancer: A Review of the Methodological Inconsistency and Complexity of the CT-Defined Body Habitus. Annals of Surgical Oncology, 2018, 25, 1381-1394.	0.7	27
61	Associations of preâ€existing coâ€morbidities with skeletal muscle mass and radiodensity in patients with nonâ€metastatic colorectal cancer. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 654-663.	2.9	55
62	Cancer-associated cachexia. Nature Reviews Disease Primers, 2018, 4, 17105.	18.1	908
63	Bridging the gap: are animal models consistent with clinical cancer cachexia?. Nature Reviews Clinical Oncology, 2018, 15, 197-198.	12.5	23
64	Low subcutaneous adiposity associates with higher mortality in female patients with cirrhosis. Journal of Hepatology, 2018, 69, 608-616.	1.8	97
65	Barriers to cancer nutrition therapy: excess catabolism of muscle and adipose tissues induced by tumour products and chemotherapy. Proceedings of the Nutrition Society, 2018, 77, 394-402.	0.4	51
66	Head and Neck Cancer Patients Do Not Meet Recommended Intakes of Micronutrients without Consuming Fortified Products. Nutrition and Cancer, 2018, 70, 474-482.	0.9	14
67	Body Composition in Relation to Clinical Outcomes in Renal Cell Cancer: A Systematic Review and Meta-analysis. European Urology Focus, 2018, 4, 420-434.	1.6	45
68	High fat mass associates with occurrence of targeted therapy-induced left ventricular ejection fraction reduction in patients with renal cell carcinoma. Clinical Nutrition, 2018, 37, 1070-1072.	2.3	1
69	Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant. Hepatology, 2018, 67, 914-923.	3.6	52
70	Differentially expressed alternatively spliced genes in skeletal muscle from cancer patients with cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 60-70.	2.9	24
71	Cancer-associated malnutrition. European Journal of Clinical Nutrition, 2018, 72, 1255-1259.	1.3	116
72	Sarcopenia and myosteatosis are accompanied by distinct biological profiles in patients with pancreatic and periampullary adenocarcinomas. PLoS ONE, 2018, 13, e0196235.	1.1	97

#	Article	IF	Citations
73	Cancer cachexia: Diagnosis, assessment, and treatment. Critical Reviews in Oncology/Hematology, 2018, 127, 91-104.	2.0	140
74	Assessment of Computed Tomography (CT)-Defined Muscle and Adipose Tissue Features in Relation to Short-Term Outcomes After Elective Surgery for Colorectal Cancer: A Multicenter Approach. Annals of Surgical Oncology, 2018, 25, 2669-2680.	0.7	87
75	Single-Nucleotide Polymorphisms in TAOK3 Are Associated With High Opioid Requirement for Pain Management in Patients With Advanced Cancer Admitted to a Tertiary Palliative Care Unit. Journal of Pain and Symptom Management, 2018, 56, 560-566.	0.6	9
76	Cancer Cachexia and Anorexia. , 2018, , 351-361.		0
77	The impact of skeletal muscle and adipose tissue on long-term survival in patients with resectable colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 3585-3585.	0.8	0
78	Small RNAome profiling from human skeletal muscle: novel miRNAs and their targets associated with cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 405-416.	2.9	74
79	Mitogen-Activated Protein Kinases Inhibitors: Potential Therapeutic Agents for Cancer Cachexia. Molecular Cancer Therapeutics, 2017, 16, 263-264.	1.9	3
80	Muscle mass and association to quality of life in nonâ€small cell lung cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 759-767.	2.9	102
81	Skeletal muscle density is an independent predictor of diffuse large Bâ€cell lymphoma outcomes treated with rituximabâ€based chemoimmunotherapy. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 298-304.	2.9	60
82	The applicability of a weight loss grading system in cancer cachexia: a longitudinal analysis. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 789-797.	2.9	58
83	Subcutaneous adiposity is an independent predictor of mortality in cancer patients. British Journal of Cancer, 2017, 117, 148-155.	2.9	167
84	International Association for Hospice and Palliative Care Endorses Volitional Death by Starvation and Dehydration. Journal of Palliative Medicine, 2017, 20, 577-577.	0.6	1
85	Can body composition be used to optimize the dose of platinum chemotherapy in lung cancer? A feasibility study. Supportive Care in Cancer, 2017, 25, 1257-1261.	1.0	11
86	Lower skeletal muscle attenuation and high visceral fat index are associated with complicated disease in patients with Crohn's disease: An exploratory study. Clinical Nutrition ESPEN, 2017, 21, 79-85.	0.5	33
87	Psoas as a sentinel muscle for sarcopenia: a flawed premise. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 527-528.	2.9	156
88	Management of Cancer Cachexia and Guidelines Implementation in a Comprehensive Cancer Center: AÂPhysician-Led Cancer Nutrition Program Adapted to the Practices of a Country. Journal of Pain and Symptom Management, 2017, 54, 387-393.e3.	0.6	13
89	ESPEN guidelines on nutrition in cancer patients. Clinical Nutrition, 2017, 36, 11-48.	2.3	1,855
90	New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 122-130.	2.9	55

#	Article	IF	Citations
91	Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, e129-e136.	1.1	44
92	Weight loss versus muscle loss: re-evaluating inclusion criteria for future cancer cachexia interventional trials. Supportive Care in Cancer, 2017, 25, 365-369.	1.0	31
93	Fish oil mitigates myosteatosis and improves chemotherapy efficacy in a preclinical model of colon cancer. PLoS ONE, 2017, 12, e0183576.	1.1	21
94	Body Composition as a Prognostic Factor of Neoadjuvant Chemotherapy Toxicity and Outcome in Patients with Locally Advanced Gastric Cancer. Journal of Gastric Cancer, 2017, 17, 74.	0.9	102
95	Cancer Cachexia: Beyond Weight Loss. Journal of Oncology Practice, 2016, 12, 1163-1171.	2.5	162
96	Recommended European Society of Parenteral and Enteral Nutrition protein and energy intakes and weight loss in patients with head and neck cancer. Head and Neck, 2016, 38, 1248-1257.	0.9	28
97	In Reply. Oncologist, 2016, 21, e2-e2.	1.9	3
98	Ken Fearon. Cell Metabolism, 2016, 24, 765-766.	7.2	0
99	Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. Clinical Nutrition, 2016, 35, 1386-1393.	2.3	103
100	Lean body mass as an independent determinant of doseâ€limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. Cancer Medicine, 2016, 5, 607-616.	1.3	119
101	Concurrent depletion of skeletal muscle, fat, and left ventricular mass in patients with cirrhosis of the liver. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 97-99.	2.9	13
102	Physiological and functional failure in chronic obstructive pulmonary disease, congestive heart failure and cancer: a debilitating intersection of sarcopenia, cachexia and breathlessness. Current Opinion in Supportive and Palliative Care, 2016, 10, 236-241.	0.5	20
103	Loss of visceral adipose tissue precedes subcutaneous adipose tissue and associates with n-6 fatty acid content. Clinical Nutrition, 2016, 35, 1347-1353.	2.3	25
104	Body Composition Assessment in Axial CT Images Using FEM-Based Automatic Segmentation of Skeletal Muscle. IEEE Transactions on Medical Imaging, 2016, 35, 512-520.	5.4	105
105	Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes. Seminars in Cell and Developmental Biology, 2016, 54, 2-10.	2.3	227
106	Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 126-135.	2.9	372
107	Identifying the Barriers and Enablers to Nutrition Care in Head and Neck and Esophageal Cancers. Journal of Parenteral and Enteral Nutrition, 2016, 40, 355-366.	1.3	46
108	The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer. Oncotarget, 2016, 7, 20293-20304.	0.8	22

#	Article	IF	Citations
109	Modeling the energetic cost of cancer as a result of altered energy metabolism: implications for cachexia. Theoretical Biology and Medical Modelling, 2015, 12, 17.	2.1	60
110	Skeletal Muscle Radio-Density Is an Independent Predictor of Response and Outcomes in Follicular Lymphoma Treated with Chemoimmunotherapy. PLoS ONE, 2015, 10, e0127589.	1.1	41
111	Inactivation of the ubiquitin-specific protease 19 deubiquitinating enzyme protects against muscle wasting. FASEB Journal, 2015, 29, 3889-3898.	0.2	38
112	Let Them Eat Fish. JAMA Oncology, 2015, 1, 840.	3.4	1
113	Skeletal muscle anabolism in patients with advanced cancer. Lancet Oncology, The, 2015, 16, 13-14.	5.1	36
114	Correlates of objectively measured sedentary behavior in cancer patients with brain metastases: an application of the theory of planned behavior. Psycho-Oncology, 2015, 24, 757-762.	1.0	9
115	Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer. Lung Cancer, 2015, 90, 85-91.	0.9	68
116	Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer. Oncologist, 2015, 20, 967-974.	1.9	73
117	Inclusion of Sarcopenia Within MELD (MELD-Sarcopenia) and the Prediction of Mortality in Patients With Cirrhosis. Clinical and Translational Gastroenterology, 2015, 6, e102.	1.3	261
118	Development of a new equation to estimate creatinine clearance in cancer patients. Cancer Chemotherapy and Pharmacology, 2015, 76, 117-124.	1.1	3
119	Diagnostic Criteria for the Classification of Cancer-Associated Weight Loss. Journal of Clinical Oncology, 2015, 33, 90-99.	0.8	538
120	Defense of Elevated Body Weight Setpoint in Diet-Induced Obese Rats on Low Energy Diet Is Mediated by Loss of Melanocortin Sensitivity in the Paraventricular Hypothalamic Nucleus. PLoS ONE, 2015, 10, e0139462.	1.1	9
121	Hyperhomocysteinemia as a potential contributor of colorectal cancer development in inflammatory bowel diseases: A review. World Journal of Gastroenterology, 2015, 21, 1081.	1.4	50
122	An invitation to the 2nd Cancer Cachexia Conference, MontrÃ©al, Canada. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 181-181.	2.9	0
123	The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer. Applied Physiology, Nutrition and Metabolism, 2014, 39, 693-698.	0.9	46
124	Too little or too much are inadequate. Current Opinion in Clinical Nutrition and Metabolic Care, 2014, 17, 211-212.	1.3	2
125	Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. Liver Transplantation, 2014, 20, 640-648.	1.3	243
126	Sarcopenia is a predictor of outcomes in very elderly patients undergoing emergency surgery. Surgery, 2014, 156, 521-527.	1.0	140

#	Article	IF	Citations
127	Nutrition impact symptoms in a population cohort of head and neck cancer patients: Multivariate regression analysis of symptoms on oral intake, weight loss and survival. Oral Oncology, 2014, 50, 877-883.	0.8	97
128	Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature, 2014, 513, 100-104.	13.7	515
129	Concurrent evolution of cancer cachexia and heart failure: bilateral effects exist. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 95-104.	2.9	62
130	Associations Between Objectively Measured Physical Activity and Quality of Life in Cancer Patients With Brain Metastases. Journal of Pain and Symptom Management, 2014, 48, 322-332.	0.6	33
131	The Role of Intestinal Microbiota in Development of Irinotecan Toxicity and in Toxicity Reduction through Dietary Fibres in Rats. PLoS ONE, 2014, 9, e83644.	1.1	61
132	Clinical determinants of weight loss in patients receiving radiation and chemoirradiation for head and neck cancer: A prospective longitudinal view. Head and Neck, 2013, 35, 695-703.	0.9	66
133	Home-based functional walking program for advanced cancer patients receiving palliative care: a case series. BMC Palliative Care, 2013, 12, 22.	0.8	19
134	The head and neck symptom checklistÂ©: an instrument to evaluate nutrition impact symptoms effect on energy intake and weight loss. Supportive Care in Cancer, 2013, 21, 3127-3136.	1.0	46
135	Clinical outcomes related to muscle mass in humans with cancer and catabolic illnesses. International Journal of Biochemistry and Cell Biology, 2013, 45, 2302-2308.	1.2	120
136	FEM-based automatic segmentation of muscle and fat tissues from thoracic CT images. , 2013, , .		4
137	Understanding the mechanisms and treatment options in cancer cachexia. Nature Reviews Clinical Oncology, 2013, 10, 90-99.	12.5	729
138	Malnutrition assessment in patients with cancers of the head and neck: A call to action and consensus. Critical Reviews in Oncology/Hematology, 2013, 88, 459-476.	2.0	70
139	Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clinical Nutrition, 2013, 32, 65-72.	2.3	158
140	Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential?. American Journal of Clinical Nutrition, 2013, 98, 1012-1019.	2.2	192
141	Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index. Journal of Clinical Oncology, 2013, 31, 1539-1547.	0.8	1,920
142	Body Composition Variation and Impact of Low Skeletal Muscle Mass in Patients With Advanced Medullary Thyroid Carcinoma Treated With Vandetanib: Results From a Placebo-Controlled Study. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2401-2408.	1.8	88
143	Sarcopenia as a Prognostic Index of Nutritional Status in Concurrent Cirrhosis and Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2013, 47, 861-870.	1.1	213
144	The nutrition swing. Current Opinion in Clinical Nutrition and Metabolic Care, 2013, 16, 241-242.	1.3	2

#	Article	IF	Citations
145	Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer, 2013, 119, 3377-3384.	2.0	170
146	Clinical Trials of Cancer Cachexia Therapy, Now and Hereafter. Journal of Clinical Oncology, 2013, 31, 1257-1258.	0.8	17
147	Effects of Sample Size on Differential Gene Expression, Rank Order and Prediction Accuracy of a Gene Signature. PLoS ONE, 2013, 8, e65380.	1.1	45
148	Sarcopenia and Physical Function: In Overweight Patients with Advanced Cancer. Canadian Journal of Dietetic Practice and Research, 2013, 74, 69-74.	0.5	61
149	What Medications Are Effective in Improving Anorexia and Weight Loss in Cancer?. , 2013, , 153-157.		0
150	Siltuximab Reverses Muscle Wasting In Patients With Multicentric Castlemanâ€™s Disease. Blood, 2013, 122, 4394-4394.	0.6	4
151	Assessment of Nutritional Status in Cancer â€“ The Relationship Between Body Composition and Pharmacokinetics. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 1197-1203.	0.9	69
152	Muscle squelettique et toxicitÃ© aux traitements nÃ©oplasiques. Medecine Et Nutrition, 2013, 49, 154-157.	0.1	0
153	What Therapeutic Strategies Are Effective in Improving Anorexia and Weight Loss in Nonmalignant Disease?. , 2013, , 158-162.		0
154	Sarcopenia and functional status in overweight patients with cancer. FASEB Journal, 2013, 27, lb351.	0.2	0
155	Development of a new equation to estimate GFR in cancer patients.. Journal of Clinical Oncology, 2013, 31, e13503-e13503.	0.8	0
156	Prediction of Skeletal Muscle and Fat Mass in Patients with Advanced Cancer Using a Metabolomic Approach. Journal of Nutrition, 2012, 142, 14-21.	1.3	28
157	Muscle wasting. Current Opinion in Clinical Nutrition and Metabolic Care, 2012, 15, 209-210.	1.3	8
158	Survival. Current Opinion in Clinical Nutrition and Metabolic Care, 2012, 15, 211-212.	1.3	5
159	Severe muscle depletion in patients on the liver transplant wait list: Its prevalence and independent prognostic value. Liver Transplantation, 2012, 18, 1209-1216.	1.3	460
160	Is there a genetic cause of appetite loss?â€”an explorative study in 1,853 cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 191-198.	2.9	15
161	Muscle Wasting Is Associated With Mortality in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2012, 10, 166-173.e1.	2.4	659
162	Evaluation of the Clinical Relevance of Body Composition Parameters in Patients With Cancer Metastatic to the Liver Treated With Hepatic Arterial Infusion Chemotherapy. Nutrition and Cancer, 2012, 64, 206-217.	0.9	29

#	Article	IF	Citations
163	Advances in the Science and Application of Body Composition Measurement. Journal of Parenteral and Enteral Nutrition, 2012, 36, 96-107.	1.3	54
164	Determinants of Physical Activity in Palliative Cancer Patients: An Application of the Theory of Planned Behavior. The Journal of Supportive Oncology, 2012, 10, 30-36.	2.3	19
165	Reframing eating during chemotherapy in cancer patients with chemosensory alterations. European Journal of Oncology Nursing, 2012, 16, 483-490.	0.9	36
166	Irinotecan (CPT-11) Chemotherapy Alters Intestinal Microbiota in Tumour Bearing Rats. PLoS ONE, 2012, 7, e39764.	1.1	115
167	Dietary Patterns of Patients: With Advanced Lung or Colorectal Cancer. Canadian Journal of Dietetic Practice and Research, 2012, 73, e298-e303.	0.5	20
168	Pâ€šselectin genotype is associated with the development of cancer cachexia. EMBO Molecular Medicine, 2012, 4, 462-471.	3.3	39
169	Synthesis and evaluation of fluorobenzoylated di- and tripeptides as inhibitors of cyclooxygenase-2 (COX-2). Bioorganic and Medicinal Chemistry, 2012, 20, 2221-2226.	1.4	15
170	Body Composition, Symptoms, and Survival in Advanced Cancer Patients Referred to a Phase I Service. PLoS ONE, 2012, 7, e29330.	1.1	87
171	Prognostic role of body composition parameters in renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2012, 30, 4621-4621.	0.8	0
172	Effects of vandetanib on body composition in patients with advanced medullary thyroid carcinomas: Results from a placebo-controlled study.. Journal of Clinical Oncology, 2012, 30, 5569-5569.	0.8	0
173	Sarcopenia With Limited Mobility: An International Consensus. Journal of the American Medical Directors Association, 2011, 12, 403-409.	1.2	884
174	Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: Interrelations and associations with prognosis. Lung Cancer, 2011, 74, 516-520.	0.9	65
175	Muscle Wasting in Cancer Cachexia: Clinical Implications, Diagnosis, and Emerging Treatment Strategies. Annual Review of Medicine, 2011, 62, 265-279.	5.0	268
176	Definition and classification of cancer cachexia: an international consensus. Lancet Oncology, The, 2011, 12, 489-495.	5.1	4,015
177	Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity. Current Opinion in Clinical Nutrition and Metabolic Care, 2011, 14, 250-254.	1.3	112
178	Would you buy a new tool to improve your practice?. Current Opinion in Clinical Nutrition and Metabolic Care, 2011, 14, 221-222.	1.3	7
179	Cancer cachexia: A systematic literature review of items and domains associated with involuntary weight loss in cancer. Critical Reviews in Oncology/Hematology, 2011, 80, 114-144.	2.0	174
180	Learning to predict cancer-associated skeletal muscle wasting from 1H-NMR profiles of urinary metabolites. Metabolomics, 2011, 7, 25-34.	1.4	51

#	Article	IF	Citations
181	An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemotherapy and Pharmacology, 2011, 67, 93-101.	1.1	133
182	Pitfalls in defining and quantifying cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 71-73.	2.9	30
183	A comparison of charlson and elixhauser comorbidity measures to predict colorectal cancer survival using administrative health data. Cancer, 2011, 117, 1957-1965.	2.0	130
184	Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer, 2011, 117, 1775-1782.	2.0	225
185	Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer, 2011, 117, 3774-3780.	2.0	179
186	Synthesis and evaluation of 1,5-diaryl-substituted tetrazoles as novel selective cyclooxygenase-2 (COX-2) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1823-1826.	1.0	76
187	Nutrition Modulation of Gastrointestinal Toxicity Related to Cancer Chemotherapy. Journal of Parenteral and Enteral Nutrition, 2011, 35, 74-90.	1.3	40
188	The advantages and limitations of cross-sectional body composition analysis. Current Opinion in Supportive and Palliative Care, 2011, 5, 342-349.	0.5	75
189	Central nervous system inflammation induces muscle atrophy via activation of the hypothalamicâ€“pituitaryâ€“adrenal axis. Journal of Experimental Medicine, 2011, 208, 2449-2463.	4.2	162
190	Nutrition impact symptoms: Key determinants of reduced dietary intake, weight loss, and reduced functional capacity of patients with head and neck cancer before treatment. Head and Neck, 2010, 32, 290-300.	0.9	136
191	MAFbx/Atrogin-1 expression is a poor index of muscle proteolysis. Current Opinion in Clinical Nutrition and Metabolic Care, 2010, 13, 223-224.	1.3	59
192	Physical activity interests and preferences in palliative cancer patients. Supportive Care in Cancer, 2010, 18, 1469-1475.	1.0	80
193	Evolving classification systems for cancer cachexia: ready for clinical practice?. Supportive Care in Cancer, 2010, 18, 273-279.	1.0	77
194	Cachexia in pancreatic cancer: new treatment options and measures of success. Hpb, 2010, 12, 323-324.	0.1	68
195	Association of Skeletal Muscle Wasting With Treatment With Sorafenib in Patients With Advanced Renal Cell Carcinoma: Results From a Placebo-Controlled Study. Journal of Clinical Oncology, 2010, 28, 1054-1060.	0.8	254
196	Body composition in patients with nonâ˜small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. American Journal of Clinical Nutrition, 2010, 91, 1133S-1137S.	2.2	377
197	Prognostic Factors in Patients With Advanced Cancer: Use of the Patient-Generated Subjective Global Assessment in Survival Prediction. Journal of Clinical Oncology, 2010, 28, 4376-4383.	0.8	119
198	Cancer Cachexia and Anorexia. , 2010, , 205-212.		1

#	Article	IF	Citations
199	Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment. Clinical Cancer Research, 2009, 15, 2920-2926.	3.2	872
200	Automated segmentation of muscle and adipose tissue on CT images for human body composition analysis. Proceedings of SPIE, 2009, , .	0.8	31
201	Associations Between Physical Activity and Quality of Life in Cancer Patients Receiving Palliative Care: A Pilot Survey. Journal of Pain and Symptom Management, 2009, 38, 785-796.	0.6	58
202	A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. American Journal of Clinical Nutrition, 2009, 89, 1173-1179.	2.2	210
203	Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer. Clinical Cancer Research, 2009, 15, 6973-6979.	3.2	570
204	The emerging role of computerized tomography in assessing cancer cachexia. Current Opinion in Supportive and Palliative Care, 2009, 3, 269-275.	0.5	206
205	Single and combined supplementation of glutamine andn-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colon tumour. British Journal of Nutrition, 2009, 102, 434-442.	1.2	23
206	Cachexia: A new definition. Clinical Nutrition, 2008, 27, 793-799.	2.3	1,906
207	A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Applied Physiology, Nutrition and Metabolism, 2008, 33, 997-1006.	0.9	1,588
208	Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncology, The, 2008, 9, 629-635.	5.1	2,357
209	Reply to Letter to the Editor: a Response to the Letter of M. Tisdale. Clinical Cancer Research, 2008, 14, 2245.2-2245.	3.2	1
210	Computational modeling of cancer cachexia. Current Opinion in Clinical Nutrition and Metabolic Care, 2008, 11, 214-221.	1.3	29
211	The dermcidin gene in cancer: role in cachexia, carcinogenesis and tumour cell survival. Current Opinion in Clinical Nutrition and Metabolic Care, 2008, 11, 208-213.	1.3	21
212	Bolus Oral Glutamine Protects Rats against CPT-11-Induced Diarrhea and Differentially Activates Cytoprotective Mechanisms in Host Intestine but Not Tumor. Journal of Nutrition, 2008, 138, 740-746.	1.3	33
213	Effect of Irinotecan (CPTâ€1) on fatty acid status in rats with colorectal cancer. FASEB Journal, 2008, 22, 679-679.	0.2	1
214	Nutritional Modulation of Antitumor Efficacy and Diarrhea Toxicity Related to Irinotecan Chemotherapy in Rats Bearing the Ward Colon Tumor. Clinical Cancer Research, 2007, 13, 7146-7154.	3.2	69
215	Is There a Human Homologue to the Murine Proteolysis-Inducing Factor?. Clinical Cancer Research, 2007, 13, 4984-4992.	3.2	47
216	Shifting to conscious control: psychosocial and dietary management of anorexia by patients with advanced cancer. Palliative Medicine, 2007, 21, 227-233.	1.3	66

#	Article	IF	Citations
217	Body Composition as an Independent Determinant of 5-Fluorouracilâ€“Based Chemotherapy Toxicity. Clinical Cancer Research, 2007, 13, 3264-3268.	3.2	485
218	Chemosensory Dysfunction Is a Primary Factor in the Evolution of Declining Nutritional Status and Quality of Life in Patients With Advanced Cancer. Journal of Pain and Symptom Management, 2007, 33, 156-165.	0.6	187
219	Meeting the Amino Acid Requirements for Protein Anabolism in Cancer Cachexia. , 2006, , 631-634.		1
220	Glutamine supplementation influences immune development in the newly weaned piglet. Developmental and Comparative Immunology, 2006, 30, 1191-1202.	1.0	49
221	Investigations of Branched-Chain Amino Acids and Their Metabolites inAnimal Models of Cancer1â€“3. Journal of Nutrition, 2006, 136, 237S-242S.	1.3	89
222	Dietary patterns in patients with advanced cancer: implications for anorexia-cachexia therapy. American Journal of Clinical Nutrition, 2006, 84, 1163-1170.	2.2	95
223	Integration of amino acid metabolism during intense lactation. Current Opinion in Clinical Nutrition and Metabolic Care, 2006, 9, 48-52.	1.3	1
224	Drug Utilization Review on a Tertiary Palliative Care Unit. Journal of Pain and Symptom Management, 2006, 31, 457-464.	0.6	6
225	The management of anorexia by patients with advanced cancer: a critical review of the literature. Palliative Medicine, 2006, 20, 623-629.	1.3	31
226	Cancer-Associated Cachexia and Underlying Biological Mechanisms. Annual Review of Nutrition, 2006, 26, 435-461.	4.3	116
227	More research needed on the treatment of the cancer anorexia/cachexia syndrome. The Journal of Supportive Oncology, 2006, 4, 508-9.	2.3	1
228	USP19 is a ubiquitin-specific protease regulated in rat skeletal muscle during catabolic states. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E693-E700.	1.8	84
229	A proinflammatory tumor that activates protein degradation sensitizes rats to catabolic effects of endotoxin. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E527-E533.	1.8	6
230	Skeletal muscle protein mobilization during the progression of lactation. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E564-E572.	1.8	31
231	Effects of Exercise Training on Antitumor Efficacy of Doxorubicin in MDA-MB-231 Breast Cancer Xenografts. Clinical Cancer Research, 2005, 11, 6695-6698.	3.2	65
232	Parenteral Nutrition in Advanced Cancer: Indications and Clinical Practice Guidelines. Journal of Palliative Medicine, 2005, 8, 914-918.	0.6	20
233	Cytokines and the Pathophysiology of Skeletal Muscle Atrophy. , 2005, , 101-114.		3
234	Animal Models of Amino Acid Metabolism: A Focus on the Intestine. Journal of Nutrition, 2004, 134, 1656S-1659S.	1.3	13

#	Article	IF	Citations
235	n-3 Polyunsaturated fatty acids throughout the cancer trajectory: influence on disease incidence, progression, response to therapy and cancer-associated cachexia. Nutrition Research Reviews, 2004, 17, 177-192.	2.1	57
236	Regulation of Protein Catabolism by Muscle-Specific and Cytokine-Inducible Ubiquitin Ligase E3Î±-II during Cancer Cachexia. Cancer Research, 2004, 64, 8193-8198.	0.4	95
237	Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB Journal, 2004, 18, 39-51.	0.2	1,329
238	Understanding and managing cancer cachexia. Journal of the American College of Surgeons, 2003, 197, 143-161.	0.2	175
239	Effect of Fish Oil on Appetite and Other Symptoms in Patients With Advanced Cancer and Anorexia/Cachexia: A Double-Blind, Placebo-Controlled Study. Journal of Clinical Oncology, 2003, 21, 129-134.	0.8	280
240	EXPRESSION AND ACTIVITY OF MATRIX METALLO PROTEINASES 2 AND 9 AND THEIR INHIBITORS IN RAT LUNGS DURING THE PERINATAL PERIOD AND IN DIAPHRAGMATIC HERNIA. Experimental Lung Research, 2003, 29, 261-276.	0.5	9
241	Overview on Metabolic Adaptation to Stress. , 2003, 8, 1-13.		2
242	Modulation of intestinal protein synthesis and protease mRNA by luminal and systemic nutrients. American Journal of Physiology - Renal Physiology, 2003, 284, G1017-G1026.	1.6	33
243	Hypercatabolism and hypermetabolism in wasting states. Current Opinion in Clinical Nutrition and Metabolic Care, 2002, 5, 237-239.	1.3	33
244	A deadly combination of anorexia and hypermetabolism. Current Opinion in Clinical Nutrition and Metabolic Care, 2001, 4, 175-177.	1.3	3
245	ModÃ¨les animaux pour les Ã©tudes mÃ©taboliques et nutritionnelles lors de la croissance tumorale. Nutrition Clinique Et Metabolisme, 2001, 15, 273-285.	0.2	0
246	Management of muscle wasting in cancer-associated cachexia. Cancer, 2001, 92, 1669-1677.	2.0	67
247	Management of muscle wasting in cancer-associated cachexia. Cancer, 2001, 92, 1669-1677.	2.0	53
248	A panoply of anabolic and catabolic mediators. Current Opinion in Clinical Nutrition and Metabolic Care, 2000, 3, 169-170.	1.3	4
249	Anabolic and catabolic mediators of intestinal protein turnover: a new experimental approach. Current Opinion in Clinical Nutrition and Metabolic Care, 2000, 3, 183-189.	1.3	8
250	Regulation of skeletal-muscleâ€“protein turnover in cancer-associated cachexia. Nutrition, 2000, 16, 1015-1018.	1.1	111
251	Cytokines and endotoxin induce cytokine receptors in skeletal muscle. American Journal of Physiology - Endocrinology and Metabolism, 2000, 279, E196-E205.	1.8	71
252	Luminal Amino Acids Acutely Decrease Intestinal Mucosal Protein Synthesis and Protease mRNA in Piglets. Journal of Nutrition, 1999, 129, 1871-1878.	1.3	28

#	Article	IF	Citations
253	Amino acid nutrition and immune function in tumour-bearing rats: a comparison of glutamine-, arginine- and ornithine 2-oxoglutarate-supplemented diets. Clinical Science, 1999, 97, 657-669.	1.8	34
254	Amino acid nutrition and immune function in tumour-bearing rats: a comparison of glutamine-, arginine- and ornithine 2-oxoglutarate-supplemented diets. Clinical Science, 1999, 97, 657.	1.8	21
255	Anabolic and catabolic mediators. Current Opinion in Clinical Nutrition and Metabolic Care, 1999, 2, 195-199.	1.3	4
256	Anabolic and catabolic mediators. Current Opinion in Clinical Nutrition and Metabolic Care, 1998, 1, 241-244.	1.3	11
257	Dietary L-Glutamine Supplementation Reduces the Growth of the Morris Hepatoma 7777 in Exercise-Trained and Sedentary Rats. Journal of Nutrition, 1997, 127, 158-166.	1.3	49
258	Reduced splenocyte metabolism and immune function in rats implanted with the Morris hepatoma 7777. Metabolism: Clinical and Experimental, 1996, 45, 848-855.	1.5	12
259	Catch-up growth following Escherichia coli infection in weanling rats. Metabolism: Clinical and Experimental, 1992, 41, 208-215.	1.5	3
260	Tissue protein synthesis in lactating and dry goats. British Journal of Nutrition, 1991, 66, 451-465.	1.2	56
261	RÃ©gulation du mÃ©tabolisme protÃ©ique musculaire : importance des prostaglandines et des cytokines produites par les cellules phagocytaires mononuclÃ©aires. Nutrition Clinique Et Metabolisme, 1990, 4, 91-98.	0.2	3
262	Exercise inhibits progressive growth of the Morris hepatoma 7777 in male and female rats. Canadian Journal of Physiology and Pharmacology, 1989, 67, 864-870.	0.7	38
263	An in vitro preparation of the extensor digitorum communis muscle from the chick (Gallus) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 Physiology, 1989, 92, 555-563.	0.7	14
264	Stimulation of Muscle Protein Degradation and Prostaglandin E₂Release by Leukocytic Pyrogen (Interleukin-1). New England Journal of Medicine, 1983, 308, 553-558.	13.9	710
265	Appetite loss/cachexia: basic science. , 0, , 151-159.		0
266	Impact of Early Jejunostomy Tube Feeding on Clinical Outcome and Parameters of Body Composition in Esophageal Cancer Patients Receiving Multimodal Therapy. Annals of Surgical Oncology, 0, , .	0.7	0
267	Rapid Standardized CT-Based Method to Determine Lean Body Mass SUV for PETâ€"A Significant Improvement Over Prediction Equations. Frontiers in Oncology, 0, 12, .	1.3	0